Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PROMO: A Phase II Study of Pembrolizumab in Patients With Relapsed Or Metastatic Osteosarcoma Not Eligible for Curative Surgery

NCT03013127 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.

NCT NCT03013127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03013127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PROMO: A Phase II Study of Pembrolizumab in Patients With Relapsed Or Metastatic Osteosarcoma Not Eligible for Curative Surgery
Lead sponsor
Oslo University Hospital
Phase
Phase 2
Overall status
Terminated
Start date
May 30, 2017
Completion date
January 31, 2019
Enrollment
12 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

osteosarcoma